TR201907702T4 - Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri. - Google Patents

Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri. Download PDF

Info

Publication number
TR201907702T4
TR201907702T4 TR2019/07702T TR201907702T TR201907702T4 TR 201907702 T4 TR201907702 T4 TR 201907702T4 TR 2019/07702 T TR2019/07702 T TR 2019/07702T TR 201907702 T TR201907702 T TR 201907702T TR 201907702 T4 TR201907702 T4 TR 201907702T4
Authority
TR
Turkey
Prior art keywords
disorders
modulators
tnf activity
derivatives
relates
Prior art date
Application number
TR2019/07702T
Other languages
English (en)
Turkish (tr)
Inventor
Christopher Brookings Daniel
Elizabeth Jackson Victoria
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of TR201907702T4 publication Critical patent/TR201907702T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2019/07702T 2013-12-09 2014-12-08 Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri. TR201907702T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1321742.7A GB201321742D0 (en) 2013-12-09 2013-12-09 Therapeutic agents

Publications (1)

Publication Number Publication Date
TR201907702T4 true TR201907702T4 (tr) 2019-06-21

Family

ID=50000425

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07702T TR201907702T4 (tr) 2013-12-09 2014-12-08 Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.

Country Status (11)

Country Link
US (1) US9850240B2 (enExample)
EP (1) EP3080109B1 (enExample)
JP (1) JP6426185B2 (enExample)
CN (1) CN105814043B (enExample)
BR (1) BR112016011844B1 (enExample)
CA (1) CA2931578C (enExample)
ES (1) ES2730942T3 (enExample)
GB (1) GB201321742D0 (enExample)
RU (1) RU2677697C1 (enExample)
TR (1) TR201907702T4 (enExample)
WO (1) WO2015086496A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201321735D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2797685T3 (es) 2015-03-18 2020-12-03 Bristol Myers Squibb Co Compuestos heterocíclicos tricíclicos útiles como inhibidores de TNF
KR102696304B1 (ko) 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Tnf의 억제제로서 유용한 헤테로시클릭 화합물
EA032315B1 (ru) 2015-03-18 2019-05-31 Бристол-Маерс Сквибб Компани Замещенные трициклические гетероциклические соединения
AR104293A1 (es) 2015-04-17 2017-07-12 Abbvie Inc Indazolonas como moduladores de la señalización de tnf
US9856253B2 (en) 2015-04-17 2018-01-02 Abbvie, Inc. Tricyclic modulators of TNF signaling
US20160304496A1 (en) 2015-04-17 2016-10-20 Abbvie Inc. Indazolones as modulators of tnf signaling
GB201510758D0 (en) 2015-06-18 2015-08-05 Ucb Biopharma Sprl Novel TNFa structure for use in therapy
CN108137609B (zh) 2015-08-03 2021-07-16 百时美施贵宝公司 用作TNFα的调节剂的环状化合物
EP4467565A3 (en) 2016-12-21 2025-03-12 Amgen Inc. Anti-tnf alpha antibody formulations
GB201621907D0 (en) 2016-12-21 2017-02-01 Ucb Biopharma Sprl And Sanofi Antibody epitope
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601952B1 (fr) * 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
DE10038019A1 (de) * 2000-08-04 2002-02-14 Bayer Ag Substituierte Triazolopyrid(az)ine
KR20030080087A (ko) * 2001-03-09 2003-10-10 화이자 프로덕츠 인코포레이티드 항염증제로서의 트리아졸로피리딘
CN2783538Y (zh) 2004-08-04 2006-05-24 蒋沛康 无电线电池按扣
EP1786811A2 (en) * 2004-08-18 2007-05-23 Pharmacia & Upjohn Company LLC Triazolopyridine compounds
US7572807B2 (en) * 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
PE20121506A1 (es) * 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US7700593B2 (en) * 2006-10-11 2010-04-20 Amgen Inc. Imidazo- and triazolo-pyridine compounds and methods of use thereof
US8119658B2 (en) * 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US8324241B2 (en) * 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
FR2933980B1 (fr) * 2008-07-18 2011-07-29 Sanofi Aventis Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
AU2009272516A1 (en) * 2008-07-18 2010-01-21 Sanofi-Aventis Novel triazolo(4,3-a)pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
WO2010022081A1 (en) * 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
TWI496779B (zh) * 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物
DE102008063667A1 (de) * 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
CN102395586A (zh) * 2009-02-17 2012-03-28 奇斯药制品公司 作为p38map激酶抑制剂的三唑并吡啶衍生物
SMT201700456T1 (it) * 2009-07-27 2017-11-15 Gilead Sciences Inc Composti eterociclici fusi come modulatori dei canali ionici
FR2966471A1 (fr) * 2010-09-20 2012-04-27 Valeo Vision Piece de vehicule automobile en materiau a base de polymere (s) traite en surface
WO2012065297A1 (en) * 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
EP2755976B1 (en) * 2011-09-15 2018-07-18 Novartis AG 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors
CN103130792B (zh) * 2011-11-30 2016-05-04 正大天晴药业集团股份有限公司 一种2-氨基噻唑类化合物
CA2858420A1 (en) * 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
US9340549B2 (en) * 2012-03-05 2016-05-17 Amgen Inc. Oxazolidinone compounds and derivatives thereof
US8765767B2 (en) 2012-03-16 2014-07-01 Bristol-Myers Squibb Company Positive allosteric modulators of mGluR2
TR201807207T4 (tr) 2012-06-11 2018-06-21 Ucb Biopharma Sprl Tnf-alfa modüle edici benzimidazol bileşikleri.
GB201212513D0 (en) 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
CN104619709B (zh) 2012-07-13 2016-11-09 Ucb生物制药私人有限公司 作为tnf活性调节剂的咪唑并吡啶衍生物

Also Published As

Publication number Publication date
GB201321742D0 (en) 2014-01-22
JP6426185B2 (ja) 2018-11-21
EP3080109B1 (en) 2019-05-15
WO2015086496A1 (en) 2015-06-18
BR112016011844A2 (enExample) 2017-08-08
CA2931578C (en) 2021-10-26
EP3080109A1 (en) 2016-10-19
ES2730942T3 (es) 2019-11-13
RU2677697C1 (ru) 2019-01-21
US20160304512A1 (en) 2016-10-20
US9850240B2 (en) 2017-12-26
CA2931578A1 (en) 2015-06-18
CN105814043A (zh) 2016-07-27
CN105814043B (zh) 2019-05-17
RU2016127228A (ru) 2018-01-23
BR112016011844B1 (pt) 2022-08-16
JP2016539971A (ja) 2016-12-22

Similar Documents

Publication Publication Date Title
TR201907702T4 (tr) Tnf aktivitesinin modülatörleri olarak triazolopiridin türevleri.
TR201909614T4 (tr) Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri.
TR201908447T4 (tr) Tnf aktivitesinin modülatörleri olarak kaynaşık imidazol ve pirazol türevleri.
EA201500133A1 (ru) Производные имидазопиразина в качестве модуляторов активности tnf
EA201500130A1 (ru) Производные имидазопиридина в качестве модуляторов активности tnf
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
EA201790734A1 (ru) Конденсированные пентациклические производные имидазола
BR112016011484A2 (pt) Derivados de imidazopirimidina como moduladores de atividade de tnf
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
MY197212A (en) Fused pentacyclic imidazole derivatives as modulators of tnf activity
TR201910983T4 (tr) Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri.
BR112016013012A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112016011485A2 (pt) Derivados de imidazopiridazina como moduladores de atividade de tnf
BR112016011483A2 (pt) Derivados de imidazotriazina como moduladores de atividade de tnf
EA201401350A1 (ru) Бензимидазолы, модулирующие tnf-альфа
CA2931589C (en) Fused bicyclic heteroaromatic derivatives as modulators of tnf activity
BR112016012243A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011794A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016011792A2 (pt) Derivados de imidazopiridina como moduladores de atividade de tnf
BR112016012242A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
TR201908163T4 (tr) Tnf aktivitesinin modülatörleri olarak pirazolopiridin türevleri.
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112016011789A2 (pt) Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BR112016012254A2 (pt) Derivados de triazolpiridazina como moduladores de atividade de tnf
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf